PHARMACEUTICALLY ACCEPTABLE SALT OF CARIPRAZINE AND CRYSTAL FORM THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF
A pharmaceutically acceptable salt of cariprazine, a preparation method therefor, a pharmaceutical composition containing same, and the use thereof are provided. The pharmaceutically acceptable salt of cariprazine is a salt formed from the free base of cariprazine and an organic acid having six or more carbon atoms, and has relatively good solubility and stability.
1 . A pharmaceutically acceptable salt of cariprazine, wherein the pharmaceutically acceptable salt of cariprazine is selected from a salt formed from cariprazine free base and an organic acid having six or more carbon atoms;
preferably, the organic acid having six or more carbon atoms is a C 6 -C 30 organic acid;
for example, the C 6 -C 30 organic acid comprises, but is not limited to: hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, nonanedioic acid, decanoic acid, undecanoic acid, lauric acid, tridecanoic acid, myristic acid, pentadecanoic acid, palmitic acid, heptadecanoic acid, stearic acid, nonadecanoic acid, eicosanoic acid, oleic acid, heneicosanoic acid, docosanoic acid, tricosanoic acid, tetracosanoic acid, pentacosanoic acid, hexacosanoic acid, heptacosanoic acid, octacosanoic acid, nonacosanoic acid, triacontanoic acid, triacetin, xylonic acid, embonic acid, 1-hydroxy-2-naphthoic acid and a naphthoic acid derivative;
preferably, the naphthoic acid derivative comprises, but are not limited to, a naphthoate.
2 . The pharmaceutically acceptable salt of cariprazine as claimed in claim 1 , wherein the pharmaceutically acceptable salt of cariprazine is selected from a crystalline, polymorphic form or amorphous form, or a solvate thereof formed with a solvent;
preferably, the solvate comprises a hydrate of the pharmaceutically acceptable salt of cariprazine and a solvate formed from the pharmaceutically acceptable salt of cariprazine and an organic solvent.
3 . The pharmaceutically acceptable salt of cariprazine as claimed in claim 1 , wherein a molar ratio of cariprazine to the organic acid having six or more carbon atoms in the pharmaceutically acceptable salt is (1:0.5) to (1:2).
4 . The pharmaceutically acceptable salt of cariprazine as claimed in claim 1 , wherein the “organic solvent”in the “solvate formed from the pharmaceutically acceptable salt of cariprazine and an organic solvent”is selected from ethanol, acetone, dimethyl sulfoxide and mixtures thereof.
5 . The pharmaceutically acceptable salt of cariprazine as claimed in claim 1 , wherein the pharmaceutically acceptable salt of cariprazine is selected from at least one of crystalline forms A, F, D, B, C, E, G and I of cariprazine embonate, wherein
an X-ray powder diffraction graph of the crystalline form A of cariprazine embonate has characteristic peaks at 2θ values of 13.1°±0.2°, 18.7°±0.2°, 21.0°±0.2°, etc., preferably at 2θ values of 4.8°±0.2°, 13.1°±0.2°, 18.7°±0.2°, 20.1°±0.2°, 21.0°±0.2°, 26.1°±0.2°, etc., and more preferably at 2θ values of 4.8°±0.2°, 9.7±0.2°, 12.3°±0.2°, 13.1°±0.2°, 18.7°±0.2°, 20.1°±0.2°, 21.0°±0.2°, 26.1°±0.2°, etc.;
an X-ray powder diffraction graph of the crystalline form F of cariprazine embonate has characteristic peaks at 2θ values of 4.9°±0.2°, 19.2°±0.2°, 21.0°±0.2°, etc., preferably at 2θ values of 4.9°±0.2°, 13.6°±0.2°, 19.2°±0.2°, 21.0°±0.2°, 24.0°±0.2°, 26.3°±0.2°, etc., and more preferably at 2θ values of 4.9°±0.2°, 12.8°±0.2°, 13.6°±0.2°, 19.2°±0.2°, 20.3°±0.2°, 21.0°±0.2°, 24.0°±0.2°, 26.3°±0.2°, etc.;
an X-ray powder diffraction graph of the crystalline form D of cariprazine embonate has characteristic peaks at 2θ values of 9.6°±0.2°, 11.9°±0.2°, 20.4°±0.2°, etc., preferably at 2θ values of 9.6°±0.2°, 11.9°±0.2°, 16.6°±0.2°, 20.4°±0.2°, 24.5°±0.2°, 25.3°±0.2°, etc., and more preferably at 2θ values of 9.6°±0.2°, 11.9°±0.2°, 15.2°±0.2°, 16.6°±0.2°, 20.4°±0.2°, 20.7°±0.2°, 24.5°±0.2°, 25.3°±0.2°, etc.;
an X-ray powder diffraction graph of the crystalline form B of cariprazine embonate has characteristic peaks at 2θ values of 5.2°±0.2°, 10.5°±0.2°, 14.0°±0.2°, 14.4°±0.2°, 17.5°±0.2°, 21.3°±0.2°, 21.9°±0.2°, 22.9°±0.2°, 26.2°±0.2°, etc.;
an X-ray powder diffraction graph of the crystalline form C of cariprazine embonate has characteristic peaks at 2θ values of 8.6°±0.2°, 13.0°±0.2°, 16.8°±0.2°, 17.3°±0.2°, 18.2°±0.2°, 18.5°±0.2°, 19.8°±0.2°, 22.1°±0.2°, 23.5°±0.2°, etc.;
an X-ray powder diffraction graph of the crystalline form E of cariprazine embonate has characteristic peaks at 20 values of 11.0°±0.2°, 12.8°±0.2°, 13.8°±0.2°, 15.5°±0.2°, 15.9°±0.2°, 17.9°±0.2°, 18.4°±0.2°, 20.7°±0.2°, 23.4°±0.2°, etc.;
an X-ray powder diffraction graph of the crystalline form G of cariprazine embonate has characteristic peaks at 20 values of 8.7°±0.2°, 10.0°±0.2°, 13.6°±0.2°, 14.3°±0.2°, 17.5°±0.2°, 18.0°±0.2°, 20.3°±0.2°, 23.2°±0.2°, 25.1°±0.2°, etc.;
an X-ray powder diffraction graph of the crystalline form I of cariprazine embonate has characteristic peaks at 20 values of 10.0°±0.2°, 14.9°±0.2°, 16.3°±0.2°, 17.7°±0.2°, 18.5°±0.2°, 19.0°±0.2°, 21.1°±0.2°, 22.1°±0.2°, 24.5°±0.2°, etc.
6 . A preparation method for the pharmaceutically acceptable salt of cariprazine as claimed in claim 1 , comprising the following step:
conducting a reaction of cariprazine free base with the organic acid having six or more carbon atoms to give the pharmaceutical salt of cariprazine.
7 . A pharmaceutical composition, comprising the pharmaceutically acceptable salt of cariprazine as claimed in claim 1 .
8 . Use of the pharmaceutically acceptable salt of cariprazine as claimed in claim 1 for manufacturing a medicament for treating and/or preventing psychosis, bipolar disorder and/or acute mania.
9 . The use as claimed in claim 8 , wherein the medicament is in a dosage form selected from a tablet, a capsule, a solution, a suspension, a long-acting injection and a semisolid preparation.
10 . The use as claimed in claim 9 , wherein the suspension is an aqueous suspension, an oil suspension or a powdered suspension.